Antitrust Antitrust

AbbVie facing pay-for-delay allegations over branded blood-pressure drug Bystolic

By Max Fillion
  • 10 Jul 2020 17:35
  • 10 Jul 2020 17:35
Drugmaker AbbVie is accused of maintaining a series of agreements with generic drugmakers to delay generic competition against branded blood-pressure drug Bystolic until September 2021. The complaint, filed yesterday in California federal court, is the first pay-for-delay suit over Bystolic.

The complaint alleges that the agreements were first struck by Forest Laboratories —

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments


Latest News